CRMD
CorMedix Inc. NASDAQ Listed May 13, 2010$7.92
Mkt Cap $621.3M
52w Low $6.13
15.8% of range
52w High $17.43
50d MA $7.05
200d MA $9.80
P/E (TTM)
3.5x
EV/EBITDA
5.1x
P/B
1.4x
Debt/Equity
0.4x
ROE
40.2%
P/FCF
4.8x
RSI (14)
—
ATR (14)
—
Beta
1.41
50d MA
$7.05
200d MA
$9.80
Avg Volume
1.4M
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
300 Connell Drive · Berkeley Heights, NJ 07922 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 5, 2026 | AMC | 0.86 | 0.61 | -29.1% | 6.30 | +0.2% | +2.5% | +1.5% | +2.4% | -0.4% | -4.3% | — |
| Nov 12, 2025 | AMC | 0.48 | 0.57 | +18.8% | 11.42 | +0.0% | -1.8% | +0.3% | -11.2% | +0.9% | -0.4% | — |
| Aug 7, 2025 | AMC | 0.20 | 0.28 | +40.0% | 10.81 | -1.7% | -4.4% | -2.5% | +14.2% | +5.0% | +4.4% | — |
| May 6, 2025 | AMC | 0.25 | 0.30 | +20.0% | 11.16 | -0.6% | +4.7% | +3.0% | -3.1% | +1.7% | -1.9% | — |
| Mar 25, 2025 | AMC | 0.17 | 0.22 | +29.4% | 7.34 | +1.6% | -2.5% | -6.3% | +0.4% | -8.6% | -1.5% | — |
| Oct 30, 2024 | AMC | -0.10 | -0.05 | +50.0% | 10.05 | -0.6% | +0.1% | -0.7% | -4.0% | +5.8% | +1.7% | — |
| Aug 14, 2024 | AMC | -0.26 | -0.25 | +3.8% | 4.92 | +0.2% | -2.4% | +0.2% | +7.3% | -2.7% | -0.2% | — |
| May 9, 2024 | AMC | -0.27 | -0.25 | +7.4% | 5.41 | -0.2% | -4.4% | +2.5% | +0.6% | -1.5% | -1.0% | — |
| Mar 12, 2024 | AMC | -0.21 | -0.26 | -23.8% | 3.42 | +1.5% | +14.0% | +7.2% | -8.9% | -0.3% | +0.8% | — |
| Nov 14, 2023 | AMC | -0.21 | -0.17 | +19.0% | 3.13 | +17.3% | +6.4% | +14.1% | +5.5% | -5.7% | -4.2% | — |
| Aug 8, 2023 | AMC | -0.22 | -0.25 | -13.6% | 4.42 | -0.9% | -1.6% | +1.1% | +0.0% | -5.9% | +2.9% | — |
| May 15, 2023 | AMC | -0.20 | -0.24 | -20.0% | 5.15 | -3.7% | -13.4% | -1.8% | +1.4% | +14.9% | +0.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28 | Leerink Partners | Maintains | Outperform → Outperform | — | $7.82 | $7.89 | +0.9% | -3.2% | -1.2% | +1.5% | +2.6% | +1.4% |
| Apr 28 | RBC Capital | Maintains | Outperform → Outperform | — | $7.82 | $7.89 | +0.9% | -3.2% | -1.2% | +1.5% | +2.6% | +1.4% |
| Apr 28 | Citizens | Maintains | Market Outperform → Market Outperform | — | $7.82 | $7.89 | +0.9% | -3.2% | -1.2% | +1.5% | +2.6% | +1.4% |
| Apr 27 | Needham | Maintains | Buy → Buy | — | $7.42 | $7.53 | +1.5% | +5.4% | -3.2% | -1.2% | +1.5% | +2.6% |
| Apr 27 | D. Boral Capital | Maintains | Buy → Buy | — | $7.42 | $7.53 | +1.5% | +5.4% | -3.2% | -1.2% | +1.5% | +2.6% |
| Mar 5 | Needham | Maintains | Buy → Buy | — | $7.12 | $6.35 | -10.8% | -11.5% | +2.5% | +1.5% | +2.4% | -0.4% |
| Feb 11 | D. Boral Capital | Maintains | Buy → Buy | — | $7.69 | $7.77 | +1.0% | -3.4% | -0.9% | -0.3% | -1.8% | -0.6% |
| Jan 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.44 | $7.36 | -1.1% | -2.3% | +6.7% | -0.1% | +0.0% | +3.5% |
| Jan 21 | RBC Capital | Maintains | Outperform → Outperform | — | $6.88 | $6.88 | +0.0% | +6.5% | +1.5% | -2.3% | +6.7% | -0.1% |
| Jan 8 | Needham | Maintains | Buy → Buy | — | $11.17 | $8.74 | -21.8% | -32.8% | +1.6% | -6.3% | -1.3% | +0.4% |
| Jan 8 | D. Boral Capital | Maintains | Buy → Buy | — | $11.17 | $8.74 | -21.8% | -32.8% | +1.6% | -6.3% | -1.3% | +0.4% |
| Dec 18 | D. Boral Capital | Maintains | Buy → Buy | — | $11.45 | $11.57 | +1.0% | +4.1% | +0.8% | +3.1% | -3.3% | +1.8% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.42 | $11.42 | +0.0% | -1.8% | +0.3% | -11.2% | +0.9% | -0.4% |
| Nov 12 | Needham | Maintains | Buy → Buy | — | $11.19 | $11.74 | +4.9% | +2.1% | -1.8% | +0.3% | -11.2% | +0.9% |
| Nov 12 | D. Boral Capital | Maintains | Buy → Buy | — | $11.19 | $11.74 | +4.9% | +2.1% | -1.8% | +0.3% | -11.2% | +0.9% |
| Oct 21 | RBC Capital | Maintains | Outperform → Outperform | — | $12.16 | $12.25 | +0.7% | -4.2% | -3.9% | +1.0% | -1.2% | -1.1% |
| Oct 20 | D. Boral Capital | Upgrade | Hold → Buy | — | $10.18 | $11.78 | +15.7% | +19.4% | -4.2% | -3.9% | +1.0% | -1.2% |
| Sep 9 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $12.75 | $12.93 | +1.4% | +2.2% | -1.8% | +2.3% | -1.1% | -2.2% |
| Aug 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.81 | $10.63 | -1.7% | -4.4% | -2.5% | +14.2% | +5.0% | +4.4% |
| Jun 30 | D. Boral Capital | Downgrade | Buy → Hold | — | $12.50 | $12.64 | +1.1% | -1.4% | -4.3% | -1.7% | +0.3% | -1.7% |
| Jun 24 | Needham | Maintains | Buy → Buy | — | $16.56 | $16.89 | +2.0% | -5.1% | -4.8% | -0.1% | -16.4% | -1.4% |
| Jun 23 | D. Boral Capital | Maintains | Buy → Buy | — | $13.61 | $16.74 | +23.0% | +21.7% | -5.1% | -4.8% | -0.1% | -16.4% |
| Jun 20 | RBC Capital | Maintains | Outperform → Outperform | — | $13.58 | $13.87 | +2.1% | +0.2% | +21.7% | -5.1% | -4.8% | -0.1% |
| May 7 | Needham | Maintains | Buy → Buy | — | $11.16 | $11.09 | -0.6% | +4.7% | +3.0% | -3.1% | +1.7% | -1.9% |
| May 6 | D. Boral Capital | Maintains | Buy → Buy | — | $9.03 | $9.59 | +6.2% | +23.6% | +4.7% | +3.0% | -3.1% | +1.7% |
| Apr 9 | Needham | Maintains | Buy → Buy | — | $6.79 | $6.59 | -2.9% | +3.1% | -2.3% | +1.0% | +3.2% | +3.8% |
| Apr 8 | D. Boral Capital | Maintains | Buy → Buy | — | $6.07 | $7.51 | +23.7% | +11.9% | +3.1% | -2.3% | +1.0% | +3.2% |
| Mar 26 | RBC Capital | Maintains | Outperform → Outperform | — | $7.34 | $7.46 | +1.6% | -2.5% | -6.3% | +0.4% | -8.6% | -1.5% |
| Mar 26 | Needham | Maintains | Buy → Buy | — | $7.34 | $7.46 | +1.6% | -2.5% | -6.3% | +0.4% | -8.6% | -1.5% |
| Mar 25 | D. Boral Capital | Maintains | Buy → Buy | — | $10.77 | $8.69 | -19.3% | -31.8% | -2.5% | -6.3% | +0.4% | -8.6% |
| Mar 5 | D. Boral Capital | Maintains | Buy → Buy | — | $9.85 | $9.74 | -1.1% | +2.6% | -6.1% | +12.9% | +0.2% | -1.3% |
| Jan 22 | D. Boral Capital | Maintains | Buy → Buy | — | $12.49 | $12.50 | +0.1% | -1.5% | +0.0% | +1.0% | -0.3% | -1.8% |
| Dec 19 | RBC Capital | Maintains | Outperform → Outperform | — | $8.12 | $8.44 | +3.9% | +9.2% | -3.4% | -1.8% | -1.1% | +2.0% |
| Oct 31 | Needham | Maintains | Buy → Buy | — | $10.05 | $9.99 | -0.6% | +0.1% | -0.7% | -4.0% | +5.8% | +1.7% |
| Aug 15 | RBC Capital | Maintains | Outperform → Outperform | — | $4.92 | $4.93 | +0.2% | -2.4% | +0.2% | +7.3% | -2.7% | -0.2% |
| Aug 15 | Needham | Maintains | Buy → Buy | — | $4.92 | $4.93 | +0.2% | -2.4% | +0.2% | +7.3% | -2.7% | -0.2% |
| Jul 25 | Truist | Maintains | Buy → Buy | — | $4.77 | $4.74 | -0.6% | -1.3% | -3.6% | +3.1% | -3.4% | +1.3% |
| Jun 19 | Needham | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| May 13 | Needham | Maintains | Buy → Buy | — | $5.17 | $5.13 | -0.8% | +2.5% | +0.6% | -1.5% | -1.0% | -1.5% |
| Apr 9 | Needham | Maintains | Buy → Buy | — | $4.76 | $4.85 | +1.9% | -0.2% | +11.2% | +21.0% | -8.6% | -7.9% |
| Apr 9 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $4.76 | $4.85 | +1.9% | -0.2% | +11.2% | +21.0% | -8.6% | -7.9% |
| Mar 13 | RBC Capital | Maintains | Outperform → Outperform | — | $3.42 | $3.47 | +1.5% | +14.0% | +7.2% | -8.9% | -0.3% | +0.8% |
| Mar 12 | Needham | Maintains | Buy → Buy | — | $3.52 | $3.43 | -2.6% | -2.8% | +14.0% | +7.2% | -8.9% | -0.3% |
| Jan 31 | Truist | Maintains | Buy → Buy | — | $3.14 | $3.15 | +0.3% | -6.1% | +3.1% | +2.0% | -3.9% | -0.7% |
| Nov 15 | RBC Capital | Maintains | Outperform → Outperform | — | $3.13 | $3.67 | +17.3% | +6.4% | +14.1% | +5.5% | -5.7% | -4.2% |
| Nov 15 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $3.13 | $3.67 | +17.3% | +6.4% | +14.1% | +5.5% | -5.7% | -4.2% |
| Nov 15 | Truist | Maintains | Buy → Buy | — | $3.13 | $3.67 | +17.3% | +6.4% | +14.1% | +5.5% | -5.7% | -4.2% |
| Nov 15 | Needham | Maintains | Buy → Buy | — | $3.13 | $3.67 | +17.3% | +6.4% | +14.1% | +5.5% | -5.7% | -4.2% |
| Aug 8 | Needham | Maintains | Buy → Buy | — | $4.10 | $4.10 | +0.0% | +7.8% | -1.6% | +1.1% | +0.0% | -5.9% |
| Jun 21 | Needham | Maintains | Buy → Buy | — | $5.49 | $5.60 | +2.0% | +5.6% | -1.9% | -3.7% | -11.1% | +2.1% |
No insider trades available.
8-K · 7.01
! Medium
CorMedix Inc. -- 8-K 7.01: Regulation FD Disclosure
CorMedix announced positive Phase III topline data for REZZAYO (rezafungin) in fungal infection prophylaxis, potentially supporting regulatory approval and commercialization of this antifungal candidate.
Apr 27
8-K · 7.01
! Medium
CorMedix Inc. -- 8-K 7.01: Regulation FD Disclosure
CorMedix reaffirmed its 2027 DefenCath sales guidance of $100-$140 million, correcting an inadvertent $100-$125 million range cited on its March earnings call.
Mar 6
8-K
CorMedix Inc. -- 8-K Filing
CorMedix reported strong 2025 results with $401.3 million pro forma annual revenue and $14.0 million net income in Q4, demonstrating profitability and solid financial performance.
Mar 5
Data updated apr 25, 2026 3:16am
· Source: massive.com